Targeting inflammasome/IL-1 pathways for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The tumor microenvironment's inflammatory state influences cancer progression.
• The inflammasome pathway is crucial for producing IL-1β, a key inflammatory cytokine.
• The inflammasome's role in cancer remains debated.

Purpose of the Study:

• To investigate the role of the inflammasome and IL-1β in breast cancer progression.
• To determine if targeting the inflammasome/IL-1β pathway impacts tumor growth and metastasis.

Main Methods:

• Utilized animal and human breast cancer models.
• Assessed inflammasome activation and IL-1β levels in tumors and metastatic sites.
• Examined tumor growth and metastasis in mice deficient for inflammasome components.
• Investigated the effect of IL-1 receptor blockade (IL-1Ra) on tumor progression and myeloid cell infiltration.

Main Results:

• Inflammasome activation and elevated IL-1β levels correlate with tumor progression and metastasis.
• Mice lacking inflammasome components showed reduced tumor growth and lung metastasis.
• Inflammasome activation increased myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in tumors.
• Blocking IL-1R significantly inhibited tumor growth and metastasis, reducing myeloid cell accumulation.

Conclusions:

• The inflammasome/IL-1β pathway promotes breast cancer growth and metastasis.
• Targeting the inflammasome/IL-1β pathway, potentially via IL-1R blockade, is a promising therapeutic strategy.
• Modulating the tumor microenvironment by inhibiting this pathway may reduce pro-tumorigenic myeloid cell infiltration.